Navigation Links
Jury Rules Takeda Failed to Properly Warn a Patient and his Doctor Regarding Risks of Ingesting Diabetes Drug Actos; Parker Waichman LLP Responds

New York, New York (PRWEB) September 27, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, notes that, according to a Sept. 26 BloombergBusinessweek report, a Baltimore, Maryland-based jury has ruled that Takeda Pharmaceutical Co. failed to properly warn a patient and his doctor about the risks associated with the company’s Actos diabetes drug (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland). Jurors took over six hours during a two-day span before finding against Asia’s largest drug maker and holding it partially liable for the cancer death of the Plaintiff, BloombergBusinessweek reported, adding that the jury also ordered Takeda to pay damages of more than $1.7 million.

A Sept. 4 Bloomberg report disclosed that by 2005, Takeda officials had to have known that clinical studies were indicating the existence of links between Actos and cancer, but the company still failed to issue a warning. Six years would pass before the outfit spoke up about the risks associated with its diabetes drug. The U.S. Food and Drug Administration (FDA), which approved Actos, has been warning about Actos’s dangers since 2011. On Aug. 4 of that year, the agency issued a safety communication detailing the fact that anyone treated with Actos for more than a year faced a considerably larger risk of bladder cancer. The safety communication also noted that Actos’s label had been revised to reflect the bladder cancer risk (specifically it warned about key bladder cancer symptoms, such as bloody urine, urinary urgency or pain on urination). The updated drug label also offered healthcare professionals two recommendations:

  •     Don’t use Actos (pioglitazone) in patients with active bladder cancer.
  •     Exercise caution when using Actos to treat patients with a history of bladder cancer.

Based on Maryland law, since the jurors also found that the Plaintiff was a longtime smoker and may have contributed to his own death, the judge was required to set the verdict aside, revealed the Sept. 26 BloombergBusinessweek report.

“Notwithstanding Maryland’s stance on contributory negligence, the jury has spoken, and the jury’s decision about Takeda’s irresponsible behavior clearly supports our ongoing allegations that this drug maker failed to properly disclose the risks of Actos,” noted Parker Waichman LLP.

Aside from the FDA, research studies from other groups provide additional support for the notion of a link between Actos and bladder cancer. The British Medical Journal published a study on May 31, 2012, that revealed Actos users were twice as likely to develop bladder cancer after two years. Then, on July 3, 2012, the Canadian Medical Association Journal reported that patients taking the medication were 22 percent more likely to get bladder cancer.

Parker Waichman LLP continues to offer free legal consultations to victims of injuries allegedly caused by Actos, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

Parker Waichman LLP
Gary Falkowitz, Managing Attorney
1+ (800) LAW-INFO
1+ (800) 529-4636

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. ACO-to-MA Transition Involves Broad Array of Rules, Requirements, But Could Reap Financial Rewards, Reports ACO Business News
2. Colorado Colorado State Regulators Decide up Licensing Fees and Rules for Upcoming Recreational Pot Business, as reported by
3. Pennsylvania Athletic Trainers will Implement New PIAA rules for Heat Acclimatization in effect for 2013 Football Season
4. Zane Benefits Publishes New Information on HRA Timing Rules
5. HUMAN Healthy Vending Launches, Nation’s First Website Dedicated to USDA’s “Smart Snacks in School” Rules
6. U.S. Supreme Court Rules Generic Drug Makers Can’t Be Sued for Design Defects Under State Law, Rottenstein Law Group LLP Reports
7. Wellness Rules Prescribed for Affordable Care Act Implementation, Manage them with Healthentic
8. DePuy ASR Hip Lawsuit Update: Federal ASR Hip Lawsuit Plaintiffs Oppose Punitive Damages Rules, Rottenstein Law Group LLP Reports
9. Orriant Announced They Have Been Compliant with New Federal Rules for Corporate Wellness Programs for Nearly a Decade
10. Scott Tischler of Tischler Brothers Fitness Unveils the 7 Rules to a Healthy Diet
11. Johns Hopkins rewrites obsolete blood-ordering rules
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... Avid collector, Andrew ... Arbor Michigan boxing style concert posters. This is one of Joplin's most famous and ... House at the University of Michigan in Ann Arbor. The According to Hawley, "It ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also ... buy during the Black Friday and Cyber Monday massage chair sales to ... Internet high and low to find the best massage chair deals, they can see ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, ... in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted ... 8th through Wednesday, November 11th, 2015. The conference was held at the Hawaii ...
(Date:11/26/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the world-class Asterisk based ... efficiency and reliability. , The new Q-Suite 6 platform is based on the latest ... itself into a specific piece of software for many key components of the suite. ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... nuevo enfoque combina la inmunoterapia con la terapia fotodinámica ... Clinical Cancer Research . --> Clinical ...
(Date:11/26/2015)... , November 26, 2015 ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... has found that immunotherapy can be efficiently combined ...
Breaking Medicine Technology: